君实生物-U (688180.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−49.0x

Market Cap

CNY 35.78B

MomentumView details →

1D Return

−6.87%

YTD Return

—

RSI (14)

40.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−49.0x

Market Cap

CNY 35.78B

RSI (14)

40.5

MomentumView details →

1D Return

−6.87%

YTD Return

—

ProfitabilityView details →

Gross Margin

80.93%

Net Margin

−24.26%

EBITDA Margin

−26.26%

ROE (TTM)

−11.21%

ROA (TTM)

−4.67%

Asset Turnover

0.21x

GrowthView details →

Revenue YoY

+31.72%

EPS YoY

+46.95%

FCF YoY

+24.69%

Revenue CAGR 3Y

+19.79%

EPS CAGR 3Y

+33.08%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.04

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.74x

Current Ratio

2.14x

Quick Ratio

1.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.72B

Net Income (TTM)

−660.86M

Op. CF (TTM)

−437.39M

Next earningsOct 23, 2026 →

Latest newsMore news →

Junshi Biosciences announced the cancellation of 6.3 million H shares repurchased between May 26 and June 4, 2026, at a price of HK$17.51 per share, reducing total issued shares to 327,888,000.5d ago

Junshi Biosciences reported interim results for the six months ended June 2026, with revenue of RMB 1.696 billion, up 45% year-on-year, and a net profit of RMB 25.501 million, turning around from a loss of RMB 413 million in the same period last year.10d ago

Similar companies

Alnylam Pharmaceuticals, Inc.ALNY 万泰生物603392.SH Shanghai Henlius Biotech, Inc.02696.HK 三生国健688336.SH 3SBio Inc.01530.HK 泽璟制药-U688266.SH Find similar companies →

Latest newsMore news →

Junshi Biosciences announced the cancellation of 6.3 million H shares repurchased between May 26 and June 4, 2026, at a price of HK$17.51 per share, reducing total issued shares to 327,888,000.5d ago Junshi Biosciences reported interim results for the six months ended June 2026, with revenue of RMB 1.696 billion, up 45% year-on-year, and a net profit of RMB 25.501 million, turning around from a loss of RMB 413 million in the same period last year.10d ago